What does Privia Health do and what are its main business segments?

Did Privia Health beat or miss consensus estimates last quarter?

What guidance did Privia Health's management provide for the next earnings period?

What is the revenue and EPS growth rate for Privia Health year over year?

What factors drove the changes in Privia Health's revenue and profit?

What is Privia Health's latest dividend and current dividend yield?

What were the key takeaways from Privia Health’s earnings call?

What is Privia Health's gross profit margin?

- **Revenue & EBITDA Growth**: 16.9% practice collections growth to $3.47B, 38.8% EBITDA expansion to $125.5M.
- **Free Cash Flow Strength**: 130% EBITDA conversion in 2025, targeting 80% in 2026 with $600M cash by year-end.
- **AI & Expansion**: Investing in AI across 5 buckets; Arizona IMS partnership driving 15% Medicare Advantage growth.
- **Strategic Acquisitions**: Evolent ACO deal adds 120,000 lives, aligning with 20%+ EBITDA growth target.
- **Payer Resilience**: Diversified book (1.5M attributed lives across 130+ programs) mitigates regulatory risks.

**CEO Summary Section**
- **Revenue Growth**: Practice collections increased 16.9% to $3.47 billion in 2025, driven by new provider signings (12.3% YoY) and value-based attributed lives growth (22.7% YoY to 1.54 million).
- **EBITDA Expansion**: Adjusted EBITDA rose 38.8% to $125.5 million, with margin expanding 480 basis points to 27.2%. Free cash flow conversion was 130% of EBITDA.
- **Acquisition Impact**: Evolent Health ACO acquisition added 120,000 attributed lives, and Arizona entry via IMS partnership shows strong sales momentum.
- **2026 Guidance**: EBITDA growth of 19.5% ($150M midpoint), free cash flow conversion of 80%, and $600M cash by year-end.

**CFO Financial Commentary**
- **Q4 Results**: Practice collections grew 9.6% to $868.7M, adjusted EBITDA increased 26.4% to $31.5M (27% of care margin). Full-year EBITDA margin expanded 390 bps.
- **Cash Position**: Ended 2025 with $480M cash (vs. $11M in 2024), targeting $600M in 2026 with no new business development.
- **Free Cash Flow**: Converted 130% of EBITDA in 2025, guiding to 80% in 2026 due to becoming a full cash taxpayer.

**Q&A Highlights**
- **AI Strategy**: Investing in 5 buckets (corporate functions, provider workflows, care delivery) to enhance productivity and margins. Navina integration for clinical decision support.
- **Utilization Trends**: Elevated ambulatory utilization post-COVID expected to persist; diversified book mitigates Medicaid/ACA enrollment risks.
- **M&A Approach**: Disciplined, accretive deals (e.g., Evolent ACO) to compound EBITDA; $180M spent in 2025, no debt on balance sheet.
- **Payer Dynamics**: Shared-risk contracts preferred; navigating MA clawbacks by optimizing dense delivery networks and quality metrics.
- **Arizona Expansion**: IMS partnership driving strong sales, with focus on Medicare Advantage and Medicaid attribution growth.


Privia Health Group, Inc. (PRVA) Q4 2025 Earnings Call Transcript

- **Revenue Surge**: Q3 practice collections up 27.1% YoY to $940.4M, driven by 13.1% provider growth and 12.8% attributed lives expansion.
- **Profitability Boost**: Adjusted EBITDA jumps 61.6% to $38.2M (30.5% margin), fueled by MSSP savings of $234.1M (+32.6% YoY).
- **Strategic Deal**: $100M Evolent acquisition adds 120,000 lives in 6 new states, positioning for 2026 growth.
- **Cash Strength**: $409.9M cash on hand, enabling M&A in a consolidating healthcare market.
- **Guidance Raise**: 2025E EBITDA growth of 32%, with 12.5% attributed lives expansion.
- **Focus on Value-Based**: 80%+ of revenue from value-based contracts, reducing reliance on fee-for-service.
- **Risk Management**: Avoiding 100% capitation; prefer shared-risk models with payers.


**【CEO Summary Section】**
- **Revenue Growth**: Practice collections reached $940.4 million in Q3, up 27.1% YoY, driven by 13.1% growth in implemented providers to 5,250 and 12.8% attributed lives growth to 1.4 million.
- **Value-Based Care Performance**: Adjusted EBITDA rose 61.6% YoY to $38.2 million (30.5% care margin), with MSSP shared savings of $234.1 million (+32.6% YoY) and a 9.4% savings rate.
- **Strategic Acquisitions**: $100 million acquisition of Evolent Health's ACO business (plus $13M earn-out) adds 120,000 attributed lives across 6 new states, closing by year-end 2025.
- **Market Expansion**: National footprint now spans 15 states/D.C., 5,250 providers, and 1.4M attributed lives (+13% YoY), with Arizona fully integrated.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income $420M, Non-GAAP EPS $1.08 (vs. $0.95 prior guidance). Free cash flow $104.4M YTD, ending Q3 with $409.9M cash (no debt).
- **Guidance Update**: 2025E implemented providers +11.2% to 5,325, attributed lives +12.5%, practice collections +17.1%, EBITDA +32%.
- **Liquidity**: $410M+ cash post-acquisition, supporting M&A flexibility in a consolidating market.

**【Q&A Key Highlights】**
- **MSSP Outlook**: 2024 performance (9.4% savings rate, $234M shared savings) sets baseline for 2025, with focus on operational consistency.
- **Evolent Integration**: 6 new states with lighter ACO model, potential to convert practices to full medical group over 2-3 years.
- **MA Strategy**: Capitated book (20,000-22,000 lives) performing well, but cautious on MA risk due to market dynamics; focus on fee-for-service growth and value-based contracts.
- **Ancillary Growth**: Expanding lab, pharmacy, ASCs in high-density markets, targeting 30-35% care margin by 2026.
- **Risk Management**: Shared-risk models preferred; avoiding 100% capitation to mitigate downside.


Privia Health Group, Inc. (PRVA) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Practice Collections +18.5% YoY to $862.9M, driven by 13.8% provider growth and 15.2% attributed lives expansion.
- **Profitability**: Adjusted EBITDA +31.6% to $29M (25.2% of Care Margin), with 310bp margin expansion.
- **SaaS Model Strength**: Recurring 10-40% per-encounter fees generate stable cash flow, contrasting with peers' full-risk capitation models.
- **AI Impact**: 10-20% physician productivity gains via AI-driven workflow optimization and scribe automation.
- **Balance Sheet Strength**: $390M cash, >$450M expected by year-end. Free cash flow >80% of EBITDA.
- **Market Expansion**: Arizona IMS deal adds 150 providers, part of 15-state footprint covering 5.3M patients.

**【CEO Summary Section】**
- **Revenue Growth**: Practice Collections increased 18.5% YoY to $862.9M, driven by 13.8% YoY growth in Implemented Providers (5,125 total) and 15.2% YoY growth in value-based lives (1.38M attributed lives). 
- **Profitability**: Adjusted EBITDA rose 31.6% to $29M (25.2% of Care Margin), with a 310bp margin expansion. Full-year guidance raised to above high end of initial ranges for key metrics.
- **Model Differentiation**: Tech/SaaS fee model (recurring 10-40% per-encounter fees) combined with risk-sharing in value-based care. 98% provider retention rate and 100%+ net growth.
- **Market Expansion**: Entered Arizona via IMS acquisition, with Q4+ EBITDA contribution. 15-state footprint covering 5.3M patients across 1,300 care centers.

**【CFO Financial Commentary】**
- **Q2 Results**: GAAP revenue $420M, Adjusted EBITDA $29M. H1 Practice Collections $1.66B (+15.7%), EBITDA $55.9M (+33.3%).
- **Balance Sheet**: $390M cash (no debt), expecting >$450M by year-end. Free cash flow >80% of EBITDA due to capital-light model.
- **Guidance Update**: Raised 2025 outlook for Practice Collections, GAAP revenue, platform contribution, and EBITDA. Shared savings payments expected to accelerate in H2.

**【Q&A Key Highlights】**
- **Business Model Clarity**: CEO emphasized SaaS-like fee structure (10-40% per-encounter) vs. peers' full-risk capitation. 98% provider retention vs. industry 60-70%.
- **AI Integration**: Using AI for clinical workflow optimization (e.g., predictive condition detection), revenue cycle efficiency, and scribe automation. 10-20% physician productivity gains.
- **Market Momentum**: Record provider signings in H1, 10%+ TAM penetration in mature markets. Arizona IMS deal adds 150 providers.
- **Risk Management**: Diversified value-based book (100+ programs), no single contract >10% revenue. 31% Medicaid attributed lives growth with no downside risk.
- **Regulatory Tailwinds**: CMS fee schedule changes favoring primary care align with model. MSSP enhanced track strategy drives 10-20% margin expansion for partner practices.


Privia Health Group, Inc. (PRVA) Q2 2025 Earnings Call Transcript

- **Q1 Growth Outperformance**: 12.8% YoY Practice Collections growth, 35.1% EBITDA expansion, and 460bps margin improvement reflect strong organic execution.
- **Arizona Strategic Win**: $95M IMS acquisition adds 28,000 attributed lives, expected to be EBITDA-positive in Q4 2025 and drive 2026 growth.
- **Guidance Uptick**: Full-year 2025 EBITDA growth target raised to mid-to-high end of initial range, supported by Q1 momentum and disciplined capital allocation.
- **Risk Management**: 50-50 Medicare Advantage risk-sharing model mitigates downside, while AI-driven productivity tools enhance provider efficiency.
- **Balance Sheet Strength**: $469M cash (pre-Arizona) enables opportunistic M&A while maintaining 80%+ free cash flow conversion.


**【CEO Summary Section】**
- **Q1 2025 Performance**: Total Practice Collections grew 12.8% YoY to $798.6M, driven by 11.7% YoY growth in Implemented Providers and 11.1% YoY increase in value-based attribution. Adjusted EBITDA rose 35.1% to $26.9M, with a 460bps margin expansion to 25.6% of Care Margin.
- **Arizona Market Entry**: Acquired IMS for $95M, a 70-provider multi-specialty practice with 28,000 attributed lives. Expected to be EBITDA-positive in Q4 2025 and contribute meaningfully to 2026 EBITDA growth. Arizona's demographic trends and value-based care opportunity support long-term expansion.
- **Guidance Update**: Raised full-year 2025 guidance to mid-to-high end of initial ranges, driven by strong Q1 execution and visibility. 2025 EBITDA growth target remains 20%.

**【CFO Financial Commentary】**
- **Financial Highlights**: Ended Q1 with $469M in cash (pre-Arizona acquisition), no debt, and 80%+ free cash flow conversion. GAAP net income was $420M, with Non-GAAP EPS exceeding expectations. Capital expenditures remain minimal at $0.1M+.
- **Balance Sheet Strength**: Healthy liquidity supports disciplined M&A and organic growth. Arizona transaction reflects strategic allocation of capital to high-impact opportunities.
- **Market Position**: Operates in 15 states, serving 5.2M patients across 1,200 care centers. Commercial attributed lives grew 13.6% YoY to 779,000, with Medicare and Medicaid attribution up 5% and 11%, respectively.

**【Q&A Key Themes】**
- **Arizona Transaction Details**: IMS has 28,000 attributed lives (non-capitated), with EBITDA contribution embedded in guidance. New market entry costs (~$2-3M/year) offset byIMS's scale. Expected to be EBITDA-positive in Q4 2025.
- **Utilization Trends**: Strong ambulatory utilization (flu season, pediatric focus) drove fee-for-service growth. Fee-for-service and value-based care utilization trends expected to continue.
- **Risk Contract Strategy**: Maintains 50-50 risk-sharing in Medicare Advantage, avoiding full capitation. Focus on shared-risk arrangements with payers to manage downside risk.
- **AI and IT Initiatives**: AI-driven productivity tools (e.g., clinical documentation) adopted across 80%+ providers, improving workflow and care gaps identification. Continuous investment in value-based care analytics and RCM efficiency.
- **Market Expansion Pipeline**: 15 states operational, 35+ remaining. Arizona entry highlights disciplined approach to new market penetration, balancing upfront costs with long-term EBITDA contribution.


Privia Health Group, Inc. (PRVA) Q1 2025 Earnings Call Transcript

- **Strong 2024 Execution**: 25.2% EBITDA growth, $109M free cash flow, and 11% attributed lives expansion.
- **2025 Outlook**: 19% EBITDA growth, 80%+ cash conversion, and disciplined capital deployment.
- **Operational Efficiency**: 230bps margin expansion, 98% provider retention, and minimal new market costs in guidance.
- **Risk Management**: Positive 2% gross margin in capitated MA, prudent shared savings assumptions.

**【CEO 2024 Performance Overview】**
- **Revenue Growth**: 4.5% YoY to $2.97B, driven by 11.2% YoY increase in implemented providers and 13.6% fee-for-service collections growth.
- **Profitability**: Adjusted EBITDA up 25.2% to $90.5M, with margin expansion of 230bps to 23.1%.
- **Cash Flow**: Record $109.3M free cash flow (121% of EBITDA), ending with $491M cash and no debt.
- **Market Expansion**: 4,789 implemented providers across 14 states, 1.26M attributed lives (+11% YoY), and 98% provider retention.

**【CFO 2025 Financial Guidance】**
- **Providers**: 5,250 by year-end (+9.6% YoY).
- **Collections**: $3.2B (+7.8% YoY), with care margin growth of 8.9%.
- **EBITDA**: $107.4M (+19% YoY), targeting 200bps margin expansion.
- **Free Cash Flow**: ~$80M (80% of EBITDA), reflecting reduced NOLs and tax payments.

**【Key Q&A Highlights】**
- **OpEx Management**: 2025 OpEx growth limited to $300K YoY, driven by operating leverage in G&A and sales.
- **M&A Strategy**: Robust pipeline but disciplined; prioritizes accretive deals in existing markets.
- **Shared Savings**: 2025 guidance assumes minimal accrual growth due to Medicare Advantage headwinds.
- **Cash Utilization**: 80%+ of EBITDA to free cash; potential for M&A or shareholder returns if undervalued.

Actual	0.06	-1.68	-0.09	-0.11	-0.16	-0.1	0.01	0.14	0.06	0.06	0.05	0.02	0.02	0.03	0.03	0.03	0.03	0.02	0.05	0.07
Forecast	0.0433	-0.8523	-0.135	-0.1264	-0.0118	0.002	0.0209	0.0121	0.0615	0.056	0.0492	0.0416	0.0477	0.0452	0.0477	0.0495	0.0455	0.0497	0.0544	0.0227
Surprise	+38.57%	-97.11%	+33.33%	+12.97%	-1255.93%	-5100.00%	-52.15%	+1057.02%	-2.44%	+7.14%	+1.63%	-51.92%	-58.07%	-33.63%	-37.11%	-39.39%	-34.07%	-59.76%	-8.09%	+208.37%

PRVA

PRVA fundamentals

PRVA Q4 2025 Earnings

Earnings Call

You can ask Aime

PRVA

PRVA fundamentals

PRVA Q4 2025 Earnings

Earnings Call

PRVA Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

PRVA Earnings Call Summary for Q3/20258:00 AM on Nov 6, 2025

PRVA Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

PRVA Earnings Call Summary for Q1/20258:00 AM on May 8, 2025

PRVA Earnings Call Summary for Q4/20248:00 AM on Feb 27, 2025

You can ask Aime